Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome

Citations Over TimeTop 10% of 2021 papers

Abstract

Cytokine release syndrome (CRS) may be the key factor in the pathology of severe coronavirus disease 2019 (COVID-19). As a major driver in triggering CRS in patients with COVID-19, interleukin-6 (IL-6) appears to be a promising target for therapeutics. The results of inhibiting both trans- and classical- signaling with marketed IL-6 inhibitors (tocilizumab, siltuximab and sarilumab) in severe COVID-19 patients are effective based on several small studies and case reports thus far. In this review, we described the evidence of the IL-6 response in patients with COVID-19, clarified the pathogenesis of the role of IL-6-mediated CRS in severe COVID-19, and highlighted the rationale for the use of anti-IL-6 agents and key information regarding the potential features of these IL-6 inhibitors in COVID-19 patients.

Related Papers

• → Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19(2020)103 cited
• → Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment(2023)5 cited
• → Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome(2020)3 cited
• → Efficacy of Single Tocilizumab Administration in an 88-Year-Old Patient with Severe COVID-19 and a Mini Literature Review(2022)2 cited
• → Tocilizumab May Be a Key in Therapy for Cytokine Release Syndrome in Older Patients With Severe Symptoms of COVID-19(2020)1 cited